This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

PDF
Markdown

2022-12-31-accounts

									Period
									27/I /120
								Year Ended	to
								31/12/22	3I/'I 212/
						Unrestricted	Restricted	Total	Total
						fund	funds	funds	fiends
					Notes
INCOME	AND ENDOWMENTS			FROM
Donations	and legacies					142,178	52,906	195,084	843,501
Other trading activities						396,861		396,861	399,760
Investment	income					372		372	383
Total						539,411	52,906	592,317	/,243,644
EXPENDITURE		ON
Raising funds						270,620		270,620	292,896
Charitable	activities
Medical Equipment		Costs				8,714	307,454	316,168	804,587
Other						3,621		3,621	2,/00
Total						282,955	307,454	590,409	/,099,583
NET INCOME/(EXPENDITURE)						256,456	(254,548)	1,908	/44, 061
Transfers	between	funds			14	(293,493)	293,493
Net movement in		funds				(37,037)	38,945	1,908	144,061
RECONCILIATION			OF FUNDS
Total funds	brought	forward				70,334	73727	144,061
TOTAL FUNDS CARRIED FORWARD						33,297	112,672	145,969	144,061

						Period
						27/I //20
					Year Ended	lo
					31/12/22	3/112/21
				Notes
Cash flows from operating	activities
Cash generated from operations					(123,670)	/,036,480
Net cash (used in)/provided	by	operating		activities	(123,670)	/,036,480
Cash IIows from investing	activities
Interest received					372	383
Net cash provided by investing		activities			372	383
Change in cash and cash equivalents			in
the reporting period					(123,298)	/,036,863
Cash and cash equivalents	at	the
beginning ofthe reporting	period				I,036,863
Cash and cash equivalents	at	the end	of
the reporting period					913,565	/,036,863

RECONCILIATIO	N OF N	ET INCOME TO	NET CASH	FLOW FROM O	PERATING A	CTIVITIES
						Period
						27////20
						/o
						3///2/2/
Net income for the	reporting	period (as per the Statement		ofFinancial
Activities)					1,908	/44, 061
Adjustments for:
Interest received					(372)	(383)
Decrease/(increase)	in debtors				199,797	(229,474)
(Decrease)/increase	in creditors				(325,003)	/, 122,276
Net cash (used in)/provided		by operations			(123,670)	/,036,480
ANALYSIS OFCASH AND		CASH EQUIVALENTS
					2022	2021
Notice deposits (less than 3 inonths)					913,615	/,036,863
OverdraAs included	in bank loans and overdraAs		falling due within one year		(50)
Total cash and cash	equivalents				913,565	/,036,863
ANALYSIS OF CHANGES		IN NET FUNDS
				At I/I/22	Cash flow	At 31/12/22
				f	f
Net cash
Cash at bank				1,036,863	(123,24$)	913,615
Bank overdraA					(50)	(50)
				1,036,863	(123,29$)	913,565
Total				1,036,863	(123,298)	913,565

DONATIONS AND LEGACIES
		Period
		27/I I/20
	Year Ended	to
	31/12/22	31/12/2/
Donations	163,954	843,401
Legacies	31,130	100
	195,084	843,501

			Period
			27/I I/20
		Year Ended	to
		31/12/22	31/12/2/ f
Fundraising	events	396,86l	399,76'0
INVESTMENT INCOME
			Period
			27/I I/20
		Year Ended	to
		31/12/22	31/12/21
Deposit account interest		372	383

Raising donations and legacies
		Period
		27/I I/20
	Year Ended	ro
	31/12/22	3/112/2/
Staffcosts	104,407	58,859
Event expenses	122,095	203,/4/
Support costs	44,118	30,896
	270,620	292,896

SUPPORT COS	TS
			Governance
		Finance	costs	Totals
Raising donations	and legacies	44,118		44,118
Other resources expended		2,121	1,500	3,621
		46,239	1,500	47,739

								Period
								27/I I/20
							Year Ended	lo
							31/12/22	31/12/21
	Wages and	salaries					104,407	58,859
							104,407	58,859
	The average monthly		number ofemployees		during	the year was as follows:
								Period
								2//I I/20
							Year Ended	ro
							31/12/22	31/12/21
	Fundraising	activities					3	3
	No employees received emoluments			in excess of160,000.
10.	COMPARATIVES		FOR THE STATEMENT OF FINANCIAL ACTIVITIES
						Unrestricted	Restricted	Total
						fund	funds	funds
	INCOME	AND ENDOWMENTS		FROM
	Donations	and legacies				550,244	293,257	843,501
	Other trading activities					398,348	1,412	399,760
	Investment	income				383		383
	Total					948,975	294,669	1,243,644
	EXPENDITURE ON
	Raising funds					292,896		292,896
	Charitable	activities
	Medical Equipment		Costs			338,253	466,334	804,587
	Other					2,100		2,100
	Total					633,249	466,334	1,099,583
	NET INCOME/(EXPENDITURE)					315,726	(171,665)	144,061
	Transfers	between	funds			(245,392)	245,392
	Net movement in funds					70,334	73,727	144,061
	TOTAL FUNDS CARRIED FORWARD					70,334	73,727	144,061

II.	DEBTORS:AMOUNTS	FALLING DUE WITHIN ONE YEAR
			2022	2021
	Trade debtors		26,144	227,247
	Other debtors		303	/,071
	Prepayments and accrued	income	3,230	/, 156
			29,677	229,474
12.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
			2022	2021
	Bank loans and overdraAs	(see note 13)	50
	Trade creditors		795,248	1,104,452
	Social security and other taxes			/,474
	Accruals and deferred income		2,025	/6,350
			797,323	1,/22, 276
I3.	LOANS
	An analysis ofthe maturity	ofloans is given below:
			2022	2021
			K
	Amounts falling due within one year on demand:
	Bank overdraAs		50

MOVEMENT	IN FUNDS
			Net	Transfers
			movement	between	At
		At 1/1/22	in funds	funds	31/12/22
		f	f
Unrestricted	funds
General fund		70,334	256,456	(293,493)	33,297
Restricted funds
Closure		65,000			65,000
Andover		59		(59)
HGF Fund		7,668		(7,668)
Winchester		1,000			1,000
Urogolgy Laser			30,000	(30,000)
CAS ONE			(178,808)	178,808
Cellular Path			(12,306)	12,306
Resmon			(2,500)	2,500
Scope Guides			(63,728)	63,728
Heart Monitors			(27,206)	27,206
Bronchoscope				46,672	46,672
		73 727	(254,548)	293,493	112,672
TOTAL FUNDS		144,061	1,908		145,969
Net movement	in funds, included	in the above are as follows:
			Incoming	Resources	Movement
			resources	expended	in funds
				f	f
Unrestricted	funds
General fund			539,411	(282,955)	256,456
Restricted funds
Urogolgy Laser				30,000	30,000
CAS ONE			21,192	(200,000)	(178,808)
Cellular Path			9,999	(22,305)	(12,306)
Resmon			11,219	(13,719)	(2,500)
Scope Guides			10,496	(74,224)	(63,728)
Heart Monitors				(27,206)	(27,206)
			52,906	(307,454)	(254,548)
TOTAL FUNDS			592,317	(590,409)	1,908

			Net	Transfers
			movement	between	At
			in funds	funds	31/12/21
			f	f	f
Unrestricted	funds
General fund			315,726	(245,392)	70,334
Restricted funds
Closure			61,000	4,000	65,000
Ando ver			59		59
2020 Dri Oct	Opthlmology		(61,995)	61,995
HGF Fund			7,668		7,668
Winchester			1,000		1,000
2021 Paceports			(6,639)	6,639
2021 Mat Resus			(64,878)	64,878
Drug Storage			(2,880)	2,880
Urogolgy Laser			(105,000)	105,000
			(171,665)	245,392	73,727
TOTAL FUNDS			144,061		144,061
Comparative	net movement	in funds, included	in the above are as follows:
			Incoming	Resources	Movement
			resources f	expended	in funds
Unrestricted	funds
General fund			948,975	(633,249)	315,726
Restricted funds
Dig Deep Covid Emergency		Fund	4,188	(4,188)
Closure			61,000		61,000
Andover			59		59
2020 Radiology - Elastography			62,500	(62,500)
2020 Biometry for Opthoalmology			45,393	(45,393)
2020 Iqoro Training Device			11,600	(11,600)
2020 Dri Oct	Opthlmology		3,000	(64,995)	(61,995)
HGF Fund			7,668		7,668
2020 Hologic	Horizon Scanner		50,000	(50,000)
Winchester			1,000		1,000
2021 Paceports			7,361	(14,000)	(6,639)
2021 Mat Resus			40,400	(105,278)	(64,878)
Drug Storage				(2,880)	(2,880)
Urogolgy Laser				(105,000)	(105,000)
Dermoscopy			500	(500)
			294,669	(466,334)	(171,665)
TOTAL FUNDS			1,243,644	(1,099,583)	144,061

					Period
					27~1 I/2
				Year Ended	to
				3I/I2/22f	3//12/21
INCOME AND ENDOWMENTS
Donations and	legacies
Donations				163,954	843,401
Legacies				31,130	100
				195,084	843,50/
Other trading	activities
Fundraising events				396,861	399,760
Investment income
Deposit account interest				372	383
Total incoming	resources			592,317	1,243,644
EXPENDITURE
Raising donations		and legacies
Wages				104,407	58,859
Event expenses				122,095	203,/41
				226,502	262,000
Charitable activities
Medical equipment		costs		316,168	804,587
Support costs
Finance
Office costs				40,054	27,197
Bank charges				2,836	2,510
General expenses				3,349	2,089
				46,239	3/, 796
Governance	costs
Independent examiner's			fees	1,500	/,200
Total resources	expended			590,409	1,099,583
Net income				1,908	144,06/